{"id":"NCT01120717","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study to Assess the Long-term Safety of QVA149","officialTitle":"A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2010-05-11","resultsPosted":"2013-01-21","lastUpdate":"2013-01-31"},"enrollment":339,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"QVA149","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"QVA149","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).","primaryOutcome":{"measure":"Number of Participants With Adverse Events, Serious Adverse Events or Death","timeFrame":"52 weeks + Follow-up (Up to Day 394)","effectByArm":[{"arm":"QVA149","deltaMin":130,"sd":null},{"arm":"Placebo","deltaMin":64,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":53,"countries":["Canada","France","Hungary","India","Latvia","Lithuania","Romania","South Africa","South Korea","United Kingdom"]},"refs":{"pmids":["25677679","23867808"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":225},"commonTop":["Chronic obstructive pulmonary disease","Viral upper respiratory tract infection","Cough","Upper respiratory tract infection","Lower respiratory tract infection"]}}